Connection
Liron Caplan to Methylenetetrahydrofolate Reductase (NADPH2)
This is a "connection" page, showing publications Liron Caplan has written about Methylenetetrahydrofolate Reductase (NADPH2).
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.794 |
|
|
|
-
Davis LA, Polk B, Mann A, Wolff RK, Kerr GS, Reimold AM, Cannon GW, Mikuls TR, Caplan L. Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis. Clin Exp Rheumatol. 2014 May-Jun; 32(3):324-32.
Score: 0.408
-
Davis LA, Cannon GW, Pointer LF, Haverhals LM, Wolff RK, Mikuls TR, Reimold AM, Kerr GS, Richards JS, Johnson DS, Valuck R, Prochazka A, Caplan L. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis. J Rheumatol. 2013 Jun; 40(6):809-17.
Score: 0.386